$34M Funding Helps Speed Up New Class of Cancer Diagnostics

$34M Funding Helps Speed Up New Class of Cancer Diagnostics

282147

$34M Funding Helps Speed Up New Class of Cancer Diagnostics

InterVenn Biosciences has raised $34 million to commercialize a new diagnostic tool for ovarian cancer, based on the identification of circulating proteins containing sugar molecules (glycoproteins). The company expects to validate the diagnostic tool intended for immediate clinical use and drive rapidly expanding partnership projects. The funding will also help accelerate the use of glycoproteins in other cancer indications. “I’m humbled but inspired by the task of driving glycoproteomics as a new diagnostic nomenclature to stratify…

You must be logged in to read/download the full post.